Arcellx Inc’s recently made public that its Director Patel Kavita unloaded Company’s shares for reported $96855.0 on Feb 04 ’25. In the deal valued at $64.57 per share,1,500 shares were sold. As a result of this transaction, Patel Kavita now holds 0 shares worth roughly $0.0.
Then, Patel Kavita sold 1,500 shares, generating $98,801 in total proceeds. Upon selling the shares at $65.87, the Director now owns 0 shares.
Before that, Heery Christopher sold 4,230 shares. Arcellx Inc shares valued at $319,485 were divested by the CHIEF MEDICAL OFFICER at a price of $75.53 per share. As a result of the transaction, Heery Christopher now holds 28,638 shares, worth roughly $1.83 million.
Redburn Atlantic initiated its Arcellx Inc [ACLX] rating to a Buy in a research note published on October 08, 2024; the price target was $109. A number of analysts have revised their coverage, including Cantor Fitzgerald’s analysts, who began to cover the stock in early September with a ‘”an Overweight”‘ rating. Piper Sandler began covering ACLX with “an Overweight” recommendation on May 31, 2024. Morgan Stanley started covering the stock on March 07, 2024. It rated ACLX as “an Overweight”.
Price Performance Review of ACLX
On Friday, Arcellx Inc [NASDAQ:ACLX] saw its stock fall -2.83% to $63.75. Over the last five days, the stock has gained 0.06%. Arcellx Inc shares have fallen nearly -16.87% since the year began. Nevertheless, the stocks have risen 6.39% over the past one year. While a 52-week high of $107.37 was reached on 01/03/25, a 52-week low of $47.88 was recorded on 02/12/25. SMA at 50 days reached $71.33, while 200 days put it at $70.46.
Levels Of Support And Resistance For ACLX Stock
The 24-hour chart illustrates a support level at 62.59, which if violated will result in even more drops to 61.42. On the upside, there is a resistance level at 65.79. A further resistance level may holdings at 67.82. The Relative Strength Index (RSI) on the 14-day chart is 41.49, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.18, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 71.56%. Stochastics %K at 32.82% indicates the stock is a holding.
The most recent change occurred on January 04, 2024 when Needham resumed its ‘”a Buy”‘ rating for the stock and retained the price target to $71.
